Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression

Wen,Shuangshuang; Du,Xiaopeng; Gou,Yanyan; Jiang,Lin

doi:10.3892/ol.2016.5053

November-2016 Volume 12 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2016 Volume 12 Issue 5

Full Size Image

Article Open Access

Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression

Authors:
- Shuangshuang Wen
- Xiaopeng Du
- Yanyan Gou
- Lin Jiang
View Affiliations / Copyright

Affiliations: Department of Pharmacy, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China, Healthcare Training Center, Jinan Military General Hospital, Jinan, Shandong 250031, P.R. China, Dongying Center for Food and Drug Control, Dongying, Shandong 257091, P.R. China, Department of Oncology, Hubei Provincial Corps Hospital of The Chinese People's Armed Police Forces, Wuhan, Hubei 430060, P.R. China

Copyright: © Wen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 3187-3190
|
Published online on: August 26, 2016

https://doi.org/10.3892/ol.2016.5053
Expand metrics +

Abstract

In the present study, we analyzed the supra-additive effect of oxaliplatin in combination with gemcitabine on terminal colorectal cancer and its influence on high‑mobility group box 1 (HMGB1) expression. A total of 86 patients with terminal colorectal cancer were enrolled in this study. Patients received oxaliplatin in combination with gemcitabine. Immunohistochemistry was used to determined the subcellular localization of HMGB1 in cancer tissues as well as in para‑carcinoma tissues, and RT‑PCR and western blot analysis were used to assess the mRNA and protein expression level, respectively. The total effective rate was analyzed based on WHO tumor chemotherapy reference where complete remission (CR) implies the complete disappearance of the tumor; partial remission (PR) implies that the tumor size was reduced at least by 50%; stable disease (SD) implies that the tumor size remained unchanged and progressive disease (PD) implies an increase in the size of the tumor by ≥25%. We identified 20 cases of CR, 37 cases of PR, 12 cases of SD and 17 cases of PD. The total effective rate (CR+PR) was 66.3%. HMGB1 expression rate in the cancer tissues in the effective group was significantly lower than that in the ineffective group. Positive expression of HMGB1 protein was mainly localized in the karyon. Survival time in the patients with positive HMGB1 expression was significantly shorter than that in the patients with negative HMGB1 expression. In the effective group, HMGB1 mRNA and protein expression levels were obviously lower than those in the ineffective group. We conclude that the reduced expression rate of HMGB1 in terminal colorectal cancer cases was probably related to the effects of oxaliplatin combined with gemcitabine.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI
2	Bacchus CM, Dunfield L, Gorber S Connor, Holmes NM, Birtwhistle R, Dickinson JA, Lewin G, Singh H, Klarenbach S, Mai V, et al: Recommendations on screening for colorectal cancer in primary care. CMAJ. 22:13–15. 2016.
3	van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, et al: SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 34:1723–1731. 2016. View Article : Google Scholar : PubMed/NCBI
4	Bai M, Deng T, Han R, Zhou L and Ba Y: Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: An observational trial. Int J Clin Exp Med. 8:21159–21165. 2015.PubMed/NCBI
5	Sims GP, Rowe DC, Rietdijk ST, Herbst R and Coyle AJ: HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 28:367–388. 2010. View Article : Google Scholar : PubMed/NCBI
6	Stros M: HMGB proteins: Interactions with DNA and chromatin. Biochim Biophys Acta. 1799:101–113. 2010. View Article : Google Scholar : PubMed/NCBI
7	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta. 1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kang JW, Koh EJ and Lee SM: Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J Pineal Res. 50:403–411. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yao X, Zhao G, Yang H, Hong X, Bie L and Liu G: Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 136:677–684. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lee H, Park M, Shin N, Kim G, Kim YG, Shin JS and Kim H: High mobility group box-1 is phosphorylated by protein kinase C zeta and secreted in colon cancer cells. Biochem Biophys Res Commun. 424:321–326. 2012. View Article : Google Scholar : PubMed/NCBI
11	Hosokawa M, Saito M, Nakano A, Iwashita S, Ishizaka A, Ueda K and Iwakawa S: Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine. Oncol Lett. 10:761–767. 2015.PubMed/NCBI
12	Hosokawa Y, Watanabe M, Makino H, Mushiake H, Katsumata K, Maruno K, Fujino S and Sugiyama Y: Serum type IV collagen concentration correlates with indocyanine green retention rate and is an indicator of hepatotoxicity in patients receiving FOLFOX for colorectal cancer. Hepatogastroenterology. 62:653–656. 2015.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles